glp1versus

Bydureon BCise vs Victoza

exenatide extended-release (GLP-1 receptor agonist) vs liraglutide (GLP-1 receptor agonist) — a complete side-by-side comparison.

AstraZenecaNovo Nordisk

Bydureon BCise weight loss

2.3%

Victoza weight loss

3.2%

Bydureon BCise dosing

Once weekly

Victoza dosing

Once daily

Reviewed by Dr. Elena Vance, DOLast reviewed 10 sources cited

Quick Summary

Bydureon BCise (exenatide) and Victoza (liraglutide) are both glp-1 receptor agonists. In clinical trials, Victoza showed greater weight loss (3.2% vs 2.3%).

See the comparison table below for detailed side-by-side data.

Bydureon BCise vs Victoza: Full Comparison

FeatureBydureon BCise(exenatide extended-release)Victoza(liraglutide)
Active Ingredientexenatideliraglutide
Drug ClassGLP-1 receptor agonistGLP-1 receptor agonist
ManufacturerAstraZenecaNovo Nordisk
FDA Approved2012-01-272010-01-25
Approved Indications
  • Type 2 diabetes mellitus (adjunct to diet and exercise)
  • Type 2 diabetes mellitus (adjunct to diet and exercise)
  • Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease
  • Type 2 diabetes in patients aged 10+ years
Routesubcutaneous injectionsubcutaneous injection
FrequencyOnce weeklyOnce daily
Starting Dose2 mg weekly0.6 mg daily
Maintenance Dose2 mg weekly1.2 mg or 1.8 mg daily
Max Dose2 mg weekly1.8 mg daily
Weight Loss (%)2.3%3.2%
A1C Reduction1.3%1.1%
Key TrialDURATION-1 (30 weeks)LEADER (188 weeks)
List Price$800-$950/month$950-$1,100/month
With Insurance$25-$100/month (varies by plan)$25-$150/month (varies by plan)
Savings CardLimited savings programs available$25/month (Novo Nordisk savings card, commercially insured)

Side Effects: Bydureon BCise vs Victoza

Side EffectBydureon BCiseVictoza
Nausea11%28%
Diarrhea9%17%
Injection site nodule10-17%Not reported
Headache8%9%
Vomiting4%11%
Constipation6%6%
Pancreatitis (rare)<1%<1%
Decreased appetiteNot reported9%
DyspepsiaNot reported7%

Severity scale: 1 (mild) to 5 (serious). Based on FDA prescribing information and clinical trial data.

Related Comparisons

Bydureon BCise vs OzempicVictoza vs OzempicBydureon BCise vs WegovyVictoza vs WegovyBydureon BCise vs MounjaroVictoza vs MounjaroBydureon BCise vs ZepboundVictoza vs Zepbound

Frequently Asked Questions

Sources & References

FDA & Regulatory

  1. Bydureon BCise FDA Drugs@FDA approval record — FDA
  2. Victoza FDA Drugs@FDA approval record — FDA

Clinical Trial Records

  1. DURATION-1 clinical trial record — ClinicalTrials.gov
  2. LEADER clinical trial record — ClinicalTrials.gov

Peer-Reviewed Literature

  1. Drucker DJ et al. Exenatide once weekly versus twice daily for treatment of type 2 diabetes (DURATION-1). Lancet 2008;372:1240-1250 — The Lancet
  2. Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med 2016;375:311-322 — New England Journal of Medicine

Manufacturer Information

  1. Bydureon BCise patient website (AstraZeneca) — AstraZeneca
  2. Victoza patient and healthcare provider website — Novo Nordisk

Reference Entries

  1. Exenatide entry on Wikipedia — Wikipedia
  2. Liraglutide entry on Wikipedia — Wikipedia

This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.